The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.e

ARDS - Acute lung injury

Publications

Gibelin A, Parrot A, Maitre B, Brun-Buisson C, Mekontso Dessap A, Fartoukh M, de Prost N

Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition.

Intensive care medicine 2016 Feb;42;164-72 — 2016 Feb — 164-72

Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, Burgio MA, Amadori D, Frassineti GL

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

BMC cancer 2013 Nov 12;13;542 — 2013 Nov 12 — 542

Chi DC, Brogan F, Turenne I, Zelonis S, Schwartz L, Saif MW

Gemcitabine-induced pulmonary toxicity.

Anticancer research 2012 Sep;32;4147-9 — 2012 Sep — 4147-9

San José Ruiz B, Molas Ferrer G, Castro Rebollo P, Soy Muner D

[Interstitial pneumonitis due to gemcitabine].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2012 Sep-Oct;36;452-3 — 2012 Sep-Oct — 452-3

Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O

Drug-associated acute lung injury: a population-based cohort study.

Chest 2012 Oct;142;845-850 — 2012 Oct — 845-850

Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL

Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.

Cancer 2006 May 01;106;2051-7 — 2006 May 01 — 2051-7

Davidoff S, Shah RD, Arunabh T

Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR).

Respiratory medicine 2006 Apr;100;760-3 — 2006 Apr — 760-3

Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP

Gemcitabine-induced severe pulmonary toxicity.

Fundamental & clinical pharmacology 2004 Feb;18;85-91 — 2004 Feb — 85-91

Rosado MF, Kett DH, Schein RM, Baraona FJ, Sridhar KS

Severe pulmonary toxicity in a patient treated with gemcitabine.

American journal of clinical oncology 2002 Feb;25;31-3 — 2002 Feb — 31-3

Sauer-Heilborn A, Kath R, Schneider CP, Höffken K

Severe non-haematological toxicity after treatment with gemcitabine.

Journal of cancer research and clinical oncology 1999 Nov;125;637-40 — 1999 Nov — 637-40

Vander Els NJ, Miller V

Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.

Chest 1998 Dec;114;1779-81 — 1998 Dec — 1779-81

Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL

Diffuse alveolar damage in a patient treated with gemcitabine.

The European respiratory journal 1998 Feb;11;504-6 — 1998 Feb — 504-6